BCL2L11 and breast carcinoma: While Bcl-2 is a biomarker of resistance to both chemotherapy and radiotherapy, the association of Bim with the anti-apoptotic Bcl-2 protein may explain why Bcl-2 overexpressing lung and breast cancer cells are more sensitive to microtubule-targeting agents such as paclitaxel and vinorelbine [82].